Загрузка...
Improved Therapy by Pretargeted Radioimmunotherapy of Non-Hodgkin Lymphoma with a New Recombinant, Trivalent, Anti-CD20, Bispecific Antibody
We examined whether a pretargeting method using a new, recombinant anti-CD20 bispecific antibody (bsMAb) followed by (90)Y-DOTA-peptide could reduce hematological toxicity yet improve therapeutic responses, compared to conventional (90)Y-anti-CD20 IgG and a chemically-conjugated bsMAb. TF4, a humani...
Сохранить в:
| Главные авторы: | , , , , , , |
|---|---|
| Формат: | Статья |
| Язык: | English |
| Опубликовано: |
2008
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2585743/ https://ncbi.nlm.nih.gov/pubmed/18593929 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-08-0037 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|